AMPAR autoimmunity: Neurological and oncological accompaniments and co-existing neural autoantibodies

Jennifer A. McCombe, Cecilia Zivelonghi, Nisa Vorasoot, Masoud Majed, Eoin P. Flanagan, Divyanshu Dubey, Sean J. Pittock, Andrew McKeon, Anastasia Zekeridou

Research output: Contribution to journalArticlepeer-review


α -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor (AMPAR) encephalitis is rare but treatable. We reviewed the clinical and autoantibody profiles of 52 AMPAR-IgG-positive patients (median age 48 years [range 12–81]; 38 female) identified at the Mayo Clinic neuroimmunology laboratory. Main presentation was encephalitis; symptoms other than encephalitis associated with co-existing antibodies (p = 0.004). A tumor was found in 33/44; mostly thymoma. Most patients had partial (14/29) or complete (11/29) immunotherapy response. Thirty-one patients had at least one co-existing antibody that predicted thymoma in paraneoplastic patients (p = 0.008). In conclusion, in AMPAR encephalitis co-existing antibodies predict clinical presentation other than encephalitis and thymoma.

Original languageEnglish (US)
Article number578012
JournalJournal of neuroimmunology
StatePublished - Feb 15 2023


  • Encephalitis
  • Paraneoplastic neurological syndrome
  • Small cell lung cancer
  • Thymoma

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'AMPAR autoimmunity: Neurological and oncological accompaniments and co-existing neural autoantibodies'. Together they form a unique fingerprint.

Cite this